Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance

迈向精准免疫肿瘤学：揭示免疫治疗功效和耐药性背后的基因组决定因素和机制

• 批准号: 10252073
• 负责人: Timothy An-thy Chan
• 金额: $ 103.33万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10252073
• 关键词: Address; Affect; Animal Model; Antibodies; CTLA4 gene; Cancer Patient; Credentialing; DNA Repair; Foundations; Genetic; Genetic Determinism; Genomics; Genotype; Goals; Immune; Immunogenomics; Immunologics; Immunooncology; Immunotherapy; Individual; Malignant Neoplasms; Modeling; Molecular; Mutation; Patients; Phenotype; Pre-Clinical Model; Research; Resistance; Sampling; Somatic Mutation; Therapeutic; Treatment Efficacy; Tumor Immunity; Work; anti-CTLA4; anti-PD-1; cancer immunotherapy; density; design; driver mutation; immune checkpoint blockade; improved outcome; pre-clinical; programmed cell death ligand 1; programmed cell death protein 1; programs; response; side effect; tumor

PROJECT SUMMARY/ABSTRACT Title: Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance Immunotherapy has shown considerable promise for improving outcomes for cancer patients. Treatment of patients with antibodies against CTLA4, PD-1, or PD-L1 can result in dramatic responses and durable tumor control in some patients. However, most patients do not benefit and ICB treatment can cause severe side effects. Therefore, it is of paramount importance in the field to understand the mechanisms underlying sensitivity and resistance to ICB and other immunotherapies. The long-term goal of our research program is to unravel the molecular mechanisms underlying sensitivity and resistance to immunotherapies such as ICB and to work towards a better understanding of how to use immunotherapy in a precise and individualized manner. We propose to investigate how tumor and patient genetics/genomics affect tumor immune phenotypes and influence the response and resistance to immunotherapies. Over the next 7 years, our efforts will be focused on addressing three important questions with clear mechanistic and translational relevance. First, we will undertake a comprehensive analysis of how the diversity of mutational landscapes and densities, and DNA damage repair (DDR) deficiencies affect immunotherapy response in cancers treated with ICB (anti-PD1 or anti-CTLA4). This is aimed at developing and credentialing a precise model for ICB sensitivity and resistance to allow the design of rationale therapeutic combinations and personalization of ICB treatment. Second, we will use pre-clinical models and patient samples to evaluate how driver mutations in critical DDR mutations influence tumor immunity, ICB response, and acquired resistance. Third, we will characterize how the patient germline genotype (HLA), together with somatic mutation profiles of tumors, influence response to ICB.

项目总结/文摘